Drug Trial Radar · NCT06834932
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
432
Actual
Start
Dec 6, 2024
Primary completion
Feb 22, 2027
Study completion Feb 22, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Feb 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomised, double-blind, placebo-controlled, multi-centre, sequential Phase II and Phase III study that will evaluate the efficacy, safety, and PK of AZD0780 administered orally for up to 52 weeks in participants with elevated LDL-C. The study consist of 2 separate parts (Part A and Part B) approximately 60 participants will be randomised in Part A. There will be 2 cohorts in Part B (approximately 220 participants in Cohort 1 and 100 participants in Cohort 2).
Conditions
- Dyslipidaemia
Interventions
PlaceboDrug
Administered orally as tablets
Rosuvastatin Dose 1Drug
Administered orally as tablets
Rosuvastatin dose 2Drug
Administered orally as tablets
AZD0780Drug
Administered orally as tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- AZD0780 Concentrations in plasma (PART A)Time frame: Day 1 and Day 8: Pre-dose, 0.25,0.5,1,1.5,2,3,4,6,8,12,16 hours post-dose. Day 2, Day 9, Day 11, Day 15, Day 22, Day 29: Pre-dose (PART A)
- AZD0780 PK Parameter: AUC0-t (PART A, intensive PK subgroup).Time frame: Day 1 and Day 8: Pre-dose, 0.25,0.5,1,1.5,2,3,4,6,8,12,16 hours post-dose. Day 2, Day 9, Day 11, Day 15, Day 22, Day 29: Pre-dose (PART A)
- AZD0780 PK parameter: Cmax (PART A, intensive PK subgroup)Time frame: Day 1 and Day 8: Pre-dose, 0.25,0.5,1,1.5,2,3,4,6,8,12,16 hours post-dose. Day 2, Day 9, Day 11, Day 15, Day 22, Day 29: Pre-dose (PART A)
- AZD0780 PK parameter: AUCtau (PART A, intensive PK sub group)Time frame: Day 1 and Day 8: Pre-dose, 0.25,0.5,1,1.5,2,3,4,6,8,12,16 hours post-dose. Day 2, Day 9, Day 11, Day 15, Day 22, Day 29: Pre-dose (PART A)
- Relative change in LDL-C from baseline to 12 weeks (PART B)Time frame: From baseline to 12 weeks (PART B)
Locations
40 sites in 2 countries. Site status is shown where the registry gives one.
Research Site
Baotou, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Bengbu, China
Research Site
Changchun, China
Research Site
Changchun, China
Research Site
Changde, China
Research Site
Changsha, China
Research Site
Changzhou, China
Research Site
Chengdu, China
Research Site
Chongqing, China
Research Site
Daqing, China
Research Site
Deyang, China
Research Site
Guangzhou, China
Research Site
Guangzhou, China
Research Site
Hengyang, China
Research Site
Heze, China
Research Site
Linhai, China
Research Site
Luoyang, China
Research Site
Nanchang, China
Research Site
Nanchong, China
Research Site
Nanjing, China
Research Site
Pingxiang, China
Research Site
Qiqihar, China
Research Site
Sanya, China
Research Site
Shanghai, China
Research Site
Shanghai, China
Research Site
Shenyang, China
Research Site
Shenyang, China
Research Site
Siping, China
Research Site
Taiyuan, China
Research Site
Tianjin, China
Research Site
Wuhan, China
Research Site
Wuhan, China
Research Site
Wuhan, China
Research Site
Xi'an, China
Research Site
Xianyang, China
Research Site
Yinchuan, China
Research Site
Zigong, China
Research Site
Hong Kong, Hong Kong
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.